SynthesisMedicine2020

Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma.

Jianxin Chen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.